Machine signal
Active cluster sell — 4 distinct insiders, $6.8M, window ends Nov 16, 2026.
Figures computed from official regulatory filings — .
Analysttarget 94.43 USD (+35%) · consensus 4.38/5 · 6 buy · 2 hold · 0 sell
Ownershipinsiders 3.21% · institutions 102.32% · short 13.9% of float · 4.89d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CareDx, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Market information source · Nov 16, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Nov 16, 2026
Purchases and sales · full history
153 buys311 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Riggsbee Richard Bryan | Sell | $179K | SEC | ||
| Riggsbee Richard Bryan | Sell | $124.6K | SEC | ||
| Riggsbee Richard Bryan | Sell | $30.8K | SEC | ||
| Riggsbee Richard Bryan | Sell | $60.8K | SEC | ||
| Kennedy Keith | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Kennedy Keith | Sell | $103.3K | SEC | ||
| Kennedy Keith | Exercise | $61.7K | SEC | ||
| Goldberg Michael | Sell | $636.5K | SEC | ||
| Kennedy Keith | Sell | $63K | SEC | ||
| Goldberg Michael | Sell | $277.8K | SEC | ||
| Goldberg Michael | Sell | $178K | SEC | ||
| Novack Jeffrey Adam | Sell | $16.2K | SEC | ||
| Novack Jeffrey Adam | Sell | $241.1K | Unusual size | SEC | |
| Bickerstaff Georgetrack record | Exercise | $221.1K | Unusual size | SEC | |
| Bickerstaff Georgetrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Novack Jeffrey Adam | Sell | $75K | SEC | ||
| Kennedy Keith | Sell | $24.6K | SEC | ||
| Novack Jeffrey Adam | Other | $118.2K | SEC | ||
| Kennedy Keith | Sell | $273.5K | SEC | ||
| Kennedy Keith | Exercise | $1.5M | Unusual size | SEC | |
| Kennedy Keith | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Kennedy Keith | Sell | $958.4K | SEC | ||
| Kennedy Keith | Sell | $50.2K | SEC | ||
| Kennedy Keith | Sell | $589.4K | SEC | ||
| Kennedy Keith | Sell | $220.6K | SEC |